Nervous System Disorders

I. Structure and Function of the Nervous System

1.1 Organization of the Nervous System

The nervous system is anatomically divided into the Central Nervous System (CNS) and the Peripheral Nervous System (PNS). The CNS comprises the brain and spinal cord, while the PNS includes cranial nerves, spinal nerves, and their pathways. Functionally, the PNS is further subdivided into the somatic nervous system (voluntary control of skeletal muscles) and the autonomic nervous system (involuntary control of internal organs).

Clinical Relevance:

Understanding this division is crucial for pharmacotherapy. Drugs targeting the CNS must cross the blood-brain barrier, while PNS-acting drugs may have more peripheral effects. Autonomic nervous system drugs are particularly important in managing conditions like hypertension, asthma, and gastrointestinal disorders.

1.2 Neurons and Neuroglia

Neurons are the primary functional units responsible for nerve impulse conduction. They consist of a cell body (soma), dendrites (receiving impulses), and axons (transmitting impulses away from the cell body). Axons are often myelinated by Schwann cells in the PNS and oligodendrocytes in the CNS, which insulate the axon and enable saltatory conduction.

Neuroglia (glial cells) support and protect neurons. Key types include:

Astrocytes: Maintain blood-brain barrier, provide nutrients
Oligodendrocytes: Form myelin sheaths in CNS
Microglia: CNS immune cells
Ependymal cells: Line ventricles and produce CSF

1.3 Neurotransmission and Synapses

Neurons communicate via synapses through chemical and electrical conduction. Neurotransmitters are released from presynaptic neurons and bind to receptors on postsynaptic neurons. Key neurotransmitters include:

Neurotransmitter	Primary Function	Clinical Significance
Acetylcholine (ACh)	Muscle contraction, autonomic function, learning	Target in myasthenia gravis, Alzheimer's disease
Dopamine	Movement, reward, motivation	Parkinson's disease, schizophrenia
Norepinephrine (NE)	Arousal, attention, stress response	Depression, anxiety disorders
Serotonin	Mood, sleep, appetite	Depression, migraine, anxiety
GABA	Primary inhibitory neurotransmitter	Anxiety, epilepsy, insomnia
Glutamate	Primary excitatory neurotransmitter	Stroke, neurodegenerative diseases

1.4 Autonomic Nervous System (ANS)

The ANS maintains homeostasis through sympathetic ("fight or flight") and parasympathetic ("rest and digest") divisions. These systems work in opposition to regulate organ function.

Pharmacology Connection:

ANS drugs are classified based on their receptor targets: adrenergic (α and β receptors) and cholinergic (muscarinic and nicotinic receptors). Understanding receptor distribution is essential for predicting drug effects and side effects. For example, β-blockers reduce heart rate and blood pressure but may cause bronchoconstriction in asthmatic patients due to β₂ receptor blockade in lungs.

II. Pain, Temperature, Sleep, and Sensory Function

2.1 Neuroanatomy and Physiology of Pain

Nociception refers to the neural processing of noxious stimuli. Specialized nerve endings (nociceptors) respond to chemical, mechanical, and thermal stimuli. Pain pathways primarily travel via spinothalamic tracts to the thalamus and cerebral cortex.

Pain Assessment Principle:

"Pain is whatever the experiencing person says it is, existing whenever he says it does" (McCaffrey). This patient-centered approach is fundamental in clinical practice, especially when assessing and treating chronic pain conditions.

2.2 Pain Modulation and Endogenous Opioids

The body has endogenous pain-modulating systems. Key endogenous opioids include:

Endorphins: Inhibit pain transmission in CNS
Enkephalins: Act locally to reduce pain
Dynorphins: Complex effects, can sometimes stimulate pain

Exogenous opioids (morphine, fentanyl, etc.) mimic these endogenous compounds by binding to μ, κ, and δ opioid receptors.

2.3 Acute vs. Chronic Pain

Acute pain serves a protective function and is typically associated with sympathetic activation (tachycardia, hypertension, anxiety). Chronic pain persists beyond normal healing time (≥3-6 months) and can lead to significant behavioral and psychological changes.

2.4 Neuropathic Pain

Results from damage to or disease of the somatosensory nervous system. Examples include diabetic neuropathy and phantom limb pain. Treatment often requires adjuvant medications like antidepressants (TCAs, SNRIs) or anticonvulsants (gabapentin, pregabalin) in addition to traditional analgesics.

2.5 Temperature Regulation and Fever

The hypothalamus acts as the body's thermostat. Fever results from pyrogens (exogenous or endogenous) resetting the hypothalamic set point. Prostaglandin E₂ synthesis is a key step, which is why NSAIDs (which inhibit cyclooxygenase) are effective antipyretics.

Drug Therapy Considerations:

When treating fever, consider the underlying cause. Antipyretics like acetaminophen or NSAIDs provide symptomatic relief but don't treat infection. In hyperthermia (not mediated by pyrogens), antipyretics are ineffective, and physical cooling methods are required.

III. Alterations in Cognitive Systems, Cerebral Dynamics, and Motor Function

3.1 Levels of Consciousness

Consciousness involves both arousal (wakefulness) and awareness. Alterations range from confusion to coma. The Reticular Activating System (RAS) in the brainstem is crucial for maintaining wakefulness.

3.2 Seizure Disorders

Seizures result from abnormal, excessive, synchronous neuronal discharges. They are classified as focal (originating in one hemisphere) or generalized (involving both hemispheres).

Pharmacotherapy Approach:

Antiepileptic drug selection depends on seizure type, patient characteristics, and drug interactions. Many AEDs have narrow therapeutic indices requiring therapeutic drug monitoring. Enzyme-inducing AEDs (phenytoin, carbamazepine) can reduce efficacy of other medications including oral contraceptives.

3.3 Neurodegenerative Disorders

Alzheimer Disease (AD)

Progressive dementia with characteristic neuropathology: neurofibrillary tangles (hyperphosphorylated tau protein) and senile plaques (amyloid-β deposits). Cholinergic deficiency is prominent, leading to the use of acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine). Memantine, an NMDA receptor antagonist, is used for moderate to severe AD.

Parkinson Disease (PD)

Characterized by degeneration of dopaminergic neurons in substantia nigra, leading to dopamine depletion in striatum. Motor symptoms include tremor, rigidity, bradykinesia, and postural instability. Pharmacotherapy aims to restore dopaminergic activity (levodopa, dopamine agonists) or inhibit cholinergic overactivity (anticholinergics).

Huntington Disease (HD)

Autosomal dominant disorder causing degeneration of GABAergic neurons in basal ganglia. Chorea (involuntary dance-like movements) is characteristic. Treatment is symptomatic as no disease-modifying therapy exists.

IV. Disorders of the Central and Peripheral Nervous Systems

4.1 Cerebrovascular Disorders

Stroke Classification

Ischemic stroke (87%): Thrombotic or embolic occlusion
Hemorrhagic stroke (13%): Intracerebral or subarachnoid hemorrhage

Transient Ischemic Attacks (TIAs) are brief episodes of neurological dysfunction without acute infarction. They are important warning signs for impending stroke.

Acute Stroke Management:

Time is brain! For ischemic stroke, alteplase (tPA) must be administered within 4.5 hours of symptom onset. Contraindications include recent surgery, hemorrhage, or anticoagulant use. Secondary prevention includes antiplatelets (aspirin, clopidogrel) or anticoagulants (warfarin, DOACs) for atrial fibrillation, plus statins and antihypertensives.

4.2 Demyelinating Disorders

Multiple Sclerosis (MS)

Autoimmune inflammatory demyelination of CNS. Characterized by relapses and remissions. Disease-modifying therapies include interferon-β, glatiramer acetate, and newer agents like natalizumab, fingolimod, and ocrelizumab. Acute exacerbations are treated with corticosteroids.

4.3 Neuromuscular Junction Disorders

Myasthenia Gravis (MG)

Autoantibodies against acetylcholine receptors at neuromuscular junction cause muscle weakness and fatigue. Treatment includes acetylcholinesterase inhibitors (pyridostigmine), immunosuppressants (corticosteroids, azathioprine), and thymectomy. Acute exacerbations (myasthenic crisis) may require plasmapheresis or IV immunoglobulin.

Drug Interactions Warning:

Many drugs can exacerbate MG symptoms, including aminoglycosides, fluoroquinolones, beta-blockers, and magnesium. Pharmacists must screen for these when counseling MG patients.

4.4 CNS Infections

Meningitis

Inflammation of meninges. Bacterial meningitis is a medical emergency requiring immediate empiric antibiotics (vancomycin + third-generation cephalosporin). Empiric therapy is adjusted based on CSF culture results and patient factors (age, immunocompromise).

4.5 Traumatic Brain and Spinal Cord Injury

Management focuses on preventing secondary injury from ischemia, edema, and increased intracranial pressure. Pharmacologic interventions may include osmotic diuretics (mannitol), hypertonic saline, antiseizure prophylaxis, and careful blood pressure management.

V. Clinical Pharmacy Considerations in Neurologic Disorders

5.1 Blood-Brain Barrier (BBB) Considerations

The BBB significantly limits drug penetration into CNS. Factors affecting CNS penetration include lipid solubility, molecular size, ionization, and protein binding. Some drugs require special formulations (like liposomal preparations) or direct administration (intrathecal, intraventricular) to achieve therapeutic CNS concentrations.

5.2 Therapeutic Drug Monitoring in Neurology

Several neurologic medications require TDM:

Antiepileptic drugs: Phenytoin, carbamazepine, valproic acid
Immunosuppressants: Used in MS, myasthenia gravis
Antibiotics: For CNS infections (vancomycin, aminoglycosides)

5.3 Adverse Drug Reactions with Neurologic Manifestations

Many drugs can cause neurologic side effects:

Drug Class	Potential Neurologic ADRs	Monitoring Parameters
Antipsychotics	Extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome	Abnormal involuntary movement scale (AIMS), muscle rigidity, fever
Antiepileptics	Sedation, ataxia, cognitive impairment, peripheral neuropathy	Cognitive function, gait, serum levels
Opioids	Sedation, respiratory depression, dependence	Respiratory rate, sedation scale, signs of misuse
Chemotherapy agents	Peripheral neuropathy (vinca alkaloids, platinum compounds)	Neurologic exam, sensory symptoms

5.4 Special Populations

Geriatric Neurology

Aging affects pharmacokinetics (reduced hepatic/renal function, altered body composition) and pharmacodynamics (increased sensitivity to CNS drugs). Polypharmacy is common, increasing risk of drug interactions and adverse effects. Start low, go slow with CNS-active medications.

Pediatric Neurology

Developing nervous system has unique vulnerabilities. Drug dosing requires careful calculation based on weight or body surface area. Some AEDs have different indications or side effect profiles in children.

Medication Reconciliation Critical:

For neurologic patients, especially those with cognitive impairment or epilepsy, accurate medication histories are essential. Seizure control can be disrupted by missed doses, formulation changes, or interacting medications. Pharmacists play a key role in identifying and preventing these issues.

5.5 Emerging Therapies

Recent advances in neurology include monoclonal antibodies for migraine prevention (erenumab, fremanezumab), gene therapies for spinal muscular atrophy, and novel mechanisms for neurodegenerative diseases. Pharmacists must stay updated on these developments to appropriately counsel patients and manage expectations.